Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 16Active not recruiting 2Unknown 1Terminated 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2Gynecologic 2

Conditions

Ovarian Neoplasms 215Uterine Cervical Neoplasms 144Endometrial Neoplasms 111Fallopian Tube Neoplasms 78Breast Neoplasms 59Carcinoma, Non-Small-Cell Lung 43Colorectal Neoplasms 40Stomach Neoplasms 35Melanoma 31Carcinoma, Renal Cell 29Prostatic Neoplasms 28Neoplasms 28Carcinoma, Ovarian Epithelial 28Pancreatic Neoplasms 26Triple Negative Breast Neoplasms 25Esophageal Neoplasms 25Neoplasm Metastasis 24Lung Neoplasms 23Urinary Bladder Neoplasms 22Head and Neck Neoplasms 21Colonic Neoplasms 20Vulvar Neoplasms 19Squamous Cell Carcinoma of Head and Neck 19Carcinoma, Transitional Cell 14Carcinoma, Hepatocellular 14Uterine Neoplasms 13Small Cell Lung Carcinoma 13Sarcoma 13Rectal Neoplasms 12Peritoneal Neoplasms 12

Interventions

temsirolimus 1linrodostat 1ixabepilone 1Taxes 1Sirolimus 1Paclitaxel 1Nivolumab 1Immunoglobulin G 1Epothilones 1Disulfides 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Endometrial Adenocarcinoma × Gynecologic × Clear all
NCT00977574 2026-05-29

Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
349 enrolled 11 charts
GynecologicSarcoma

Endometrial Adenocarcinoma

NCT04106414 2025-10-14

Study of BMS-986205 and Nivolumab in Endometrial Cancer or Endometrial Carcinosarcoma That Has Not Responded to Treatment

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
24 enrolled
GynecologicSarcoma

Endometrial Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡